Embecta (EMBC) revenue breakdown
By product, Pen Needles is the largest at 73% of fiscal 2025 revenue; Safety grew fastest, 5% a year over 3 years.
By region, United States is the largest at 54% of fiscal 2025 revenue, growing 1% a year over 5 years.
Revenue by product
Fiscal years, as Embecta reports them in its 10-K filings; fiscal 2025 total $1.1B.
| Products | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| Pen Needles | $825M | $829M | $844M | $784M | 73% |
| Safety | $120M | $126M | $129M | $138M | 13% |
| Syringes | $156M | $138M | $126M | $125M | 12% |
| Contract Manufacturing | $15M | $13M | $13M | $20M | 2% |
| Other | $14M | $14M | $10M | $14M | 1% |
Revenue by region
Fiscal years, as Embecta reports them in its 10-K filings; fiscal 2025 total $1.1B.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| United States | $563M | $609M | $600M | $601M | $607M | $579M | 54% |
| International | $522M | $556M | $529M | $519M | $516M | $501M | 46% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for EMBC.
Open EMBC in InvestinglyQuestions
Where does Embecta make its money?
In fiscal 2025, by product: Pen Needles $784M, Safety $138M, Syringes $125M, Contract Manufacturing $20M, Other $14M.
From Embecta's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.